表紙
市場調査レポート

眼科治療薬市場:投薬の利便性およびコスト効率の良さが加齢性黄斑変性症(Wet-AMD)におけるEyleaの処方薬シェアを促進

Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)

発行 GBI Research 商品コード 216700
出版日 ページ情報 英文 111 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
眼科治療薬市場:投薬の利便性およびコスト効率の良さが加齢性黄斑変性症(Wet-AMD)におけるEyleaの処方薬シェアを促進 Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
出版日: 2012年10月15日 ページ情報: 英文 111 Pages
概要

世界の眼科治療薬市場では、緑内障やアレルギー性結膜炎などの分野でジェネリック医薬品が参入した影響を受けて成長は鈍化しています。しかし、加齢性黄斑変性症や糖尿病性網膜症市場におけるアンメットニーズが眼科市場を魅力的なものとしています。

当レポートでは、世界の眼科治療薬市場について調査し、市場の動向と予測、地域別動向とともに、緑内障、加齢性黄斑変性症、アレルギー性結膜炎、糖尿病性黄斑浮腫、ドライアイなどのセグメント別市場の動向と年間治療費、薬剤開発パイプライン動向、主要参入企業のプロファイルと競合動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場特性

  • イントロダクション
  • 世界の眼科市場の収益予測
    • 収益
    • 年間治療費(ACT)
  • ブランド薬とジェネリック薬の市場シェア
  • 治療使用形態
    • 有病者人口
    • 治療希望者人口
    • 診断された人口
    • 処方された人口

第4章 地域別情勢

  • 米国
  • 欧州主要5カ国
  • 日本

第5章 緑内障治療薬市場

  • イントロダクション
  • 世界市場予測
  • 年間治療費
  • ブランド薬とジェネリック薬市場シェア
  • 治療フローアルゴリズム
  • 治療使用形態
  • 米国市場予測
  • 欧州主要5カ国市場予測
  • 日本市場予測
  • 市場促進因子
    • 眼病有病率の上昇
    • 疾患診断率の上昇
  • 市場阻害因子
    • 認識不足と治療率の低さ
    • XalatanやAlphaganなどの主要な緑内障治療薬の特許失効がマイナス成長に

第6章 アレルギー性結膜炎市場

  • イントロダクション
    • 季節性アレルギー性結膜炎(SAC)
    • 通年性アレルギー性結膜炎(PAC)
  • 市場予測
  • 年間治療費
  • ブランド薬とジェネリック薬市場シェア
  • 治療フローアルゴリズム
  • 治療使用形態
  • 米国市場予測
  • 欧州主要5カ国市場予測
  • 日本市場予測
  • 市場促進因子
    • 意識向上
  • 市場阻害因子
    • 相次ぐ特許失効で市場成長が鈍化

第7章 加齢性黄斑変性症市場

  • イントロダクション
  • 世界市場予測
  • 年間治療費
  • ブランド薬とジェネリック薬市場シェア
  • 治療フローアルゴリズム
  • 治療使用形態
  • 米国市場予測
  • 欧州主要5カ国市場予測
  • 日本市場予測
  • 市場促進因子
    • 高齢化が罹患人口増加に
    • 活発な研究開発の努力が市場を促進
    • 診断ツールの改良が受診人口増加に
  • 市場阻害因子
    • 治療を求める患者率が極めて低いことが顧客セグメントの可能性を低下させている
    • 安価薬剤の未認可使用の増加が年間治療費に影響
  • 第8章 糖尿病性黄斑浮腫市場
  • イントロダクション
  • 世界市場予測
  • 年間治療費
  • ブランド薬とジェネリック薬市場シェア
  • 治療フローアルゴリズム
  • 治療使用形態
  • 米国市場予測
  • 欧州主要5カ国市場予測
  • 日本市場予測
  • 市場促進因子
    • 糖尿病などの有病率上昇が市場を促進
    • 意識向上
  • 市場阻害因子
    • レーザー治療などの効果的代替治療法が利用可能である

第9章 ドライアイ症候群市場

  • イントロダクション
  • 世界市場予測
  • 年間治療費
  • ブランド薬とジェネリック薬市場シェア
  • 治療フローアルゴリズム
  • 治療使用形態
  • 米国市場予測
  • 欧州主要5カ国市場予測
  • 日本市場予測
  • 市場促進因子
    • 有病率上昇
  • 市場阻害因子
    • 治療率の低さ
    • 不適切な治療法

第10章 糖尿病性網膜症市場

  • イントロダクション
  • 世界市場予測
  • 年間治療費
  • ブランド薬とジェネリック薬市場シェア
  • 治療フローアルゴリズム
  • 治療使用形態
  • 米国市場予測
  • 欧州主要5カ国市場予測
  • 日本市場予測
  • 市場促進因子
    • 糖尿病罹患人口の増加
    • 革新的標的療法の進歩
  • 市場阻害因子
    • 処方率の低さ
    • 後期になってからの診断

第11章 パイプライン分析

  • イントロダクション
  • 緑内障:研究開発パイプライン
  • 糖尿病性黄斑浮腫
  • 加齢性黄斑変性症
  • アレルギー性結膜炎
  • ドライアイ症候群
  • 糖尿病性網膜症

第12章 眼科治療薬市場における有望薬剤のプロファイル

第13章 競合情勢

第14章 戦略的統合

  • M&A
  • 共同開発契約
  • ライセンシング契約

第15章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The global Diabetic Macular Edema (DME) market will expand massively in the near future as a result of lifestyle changes and the introduction of more effective (and more expensive) treatments, says the latest report from pharmaceutical industry experts GBI Research.

According to their new research*, the business intelligence providers expect the global DME market to climb exponentially in value, from $43m in 2011 to a far greater $985m in 2018, exhibiting a Compound Annual Growth Rate (CAGR) of 57%.

Such dramatic growth is primarily attributed to the entrance of key treatments, including Novartis's Lucentis, which gained approval from the European Commission early last year and the US Food and Drug Administration (FDA) this year.

These approval decisions were backed by data from two Novartis-funded clinical trials, RESTORE and RESOLVE, that demonstrated that Lucentis was superior in visual acuity gain versus sham (dummy therapy) or laser therapy - the current standard of care.

Global DME market growth is predicted to be further supported by Alimera's Iluvien and Allergan's Ozurdex. The former gained European approval in June, and will be available for commercial launch by the end of the year, but was rejected by the FDA late last year over safety concerns. Ozurdex, a promising biodegradable implant, is expected to receive FDA approval in 2015.

The global ophthalmology market as a whole is expected to perform far less impressively than its DME portion, primarily due to the impending patent expiries of prostaglandin analogs used in the treatment of glaucoma.

Global industry revenue will climb, however modestly, from $10 billion in 2011 to $12 billion in 2018, at a CAGR of 2.8%.

*Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD).

This report provides insights into the global ophthalmology therapeutics market, with forecasts until 2018.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Global Ophthalmology Therapeutics Market - Introduction

  • 2.1. Overview

3. Global Ophthalmology Therapeutics Market - Market Overview

  • 3.1. Introduction
  • 3.2. Revenue
  • 3.3. Annual Cost of Treatment
  • 3.4. Treatment Usage Pattern
  • 3.5. Branded and Generic Market Share

4. Global Ophthalmology Therapeutics Market - Geographical Landscape

  • 4.1. Geographical Break-up
    • 4.1.1. The US
    • 4.1.2. Top Five Countries in Europe
    • 4.1.3. Japan

5. Global Ophthalmology Therapeutics Market - Therapeutic Landscape

  • 5.1. Glaucoma Therapeutics Market
    • 5.1.1. Introduction
    • 5.1.2. Revenue
    • 5.1.3. Annual Cost of Treatment
    • 5.1.4. Treatment Usage Pattern
    • 5.1.5. Treatment Flow Algorithm
    • 5.1.6. Branded and Generic Market Share
    • 5.1.7. Drivers for the Glaucoma Therapeutics Market
    • 5.1.8. Restraints for Glaucoma Therapeutics Market
    • 5.1.9. Geographical Segmentation
  • 5.2. Allergic Conjunctivitis Therapeutics Market
    • 5.2.1. Introduction
    • 5.2.2. Revenue
    • 5.2.3. Annual Cost of Treatment
    • 5.2.4. Treatment Usage Pattern
    • 5.2.5. Treatment Flow Algorithm
    • 5.2.6. Branded and Generic Market Share
    • 5.2.7. Geographical Segmentation
  • 5.3. Wet Age Macular Degeneration Therapeutics Market
    • 5.3.1. Introduction
    • 5.3.2. Revenue
    • 5.3.3. Annual Cost of Treatment
    • 5.3.4. Treatment Usage Pattern
    • 5.3.5. Treatment Flow Algorithm
    • 5.3.6. Branded and Generic Market Share
    • 5.3.7. Drivers for Wet Age-related Macular Degeneration Therapeutics Market
    • 5.3.8. Restraints for Wet Age-Related Macular Degeneration Therapeutics Market
    • 5.3.9. Geographical Segmentation
  • 5.4. Diabetic Macular Edema Therapeutics Market
    • 5.4.1. Introduction
    • 5.4.2. Revenue
    • 5.4.3. Annual Cost of Treatment
    • 5.4.4. Treatment Usage Pattern
    • 5.4.5. Treatment Flow Algorithm
    • 5.4.6. Drivers for Diabetic Macular Edema Therapeutics Market
    • 5.4.7. Restraints for Diabetic Macular Edema Therapeutics Market
    • 5.4.8. Geographical Segmentation
  • 5.5. Dry Eye Syndrome, Therapeutics Market
    • 5.5.1. Introduction
    • 5.5.2. Revenue
    • 5.5.3. Annual Cost of Treatment
    • 5.5.4. Treatment Usage Pattern
    • 5.5.5. Treatment Flow Algorithm
    • 5.5.6. Branded and Generic Market Share
    • 5.5.7. Drivers for Dry Eye Syndrome Therapeutics Market
    • 5.5.8. Restraints for Dry Eye Syndrome Therapeutics Market
    • 5.5.9. Geographical Segmentation

6. Global Ophthalmology Therapeutics Market - APAC

  • 6.1. India
    • 6.1.1. Overview
    • 6.1.2. Key Trends
    • 6.1.3. Key Strategies
  • 6.2. China
    • 6.2.1. Overview
    • 6.2.2. Key Trends
    • 6.2.3. Key Strategies
  • 6.3. Australia
    • 6.3.1. Overview
    • 6.3.2. Pricing and Reimbursement

7. Global Ophthalmology Therapeutics Market - Profiles of Promising Pipeline Products

  • 7.1. Iluvien (fluocinolone acetonide)
    • 7.1.1. Overview
    • 7.1.2. Efficacy
    • 7.1.3. Safety
    • 7.1.4. Clinical Study Details
  • 7.2. Rebamipide (OPC-12759E)
    • 7.2.1. Overview
    • 7.2.2. Clinical Details
  • 7.3. Remura (bromfenac)
    • 7.3.1. Overview
    • 7.3.2. Clinical details
  • 7.4. Ozurdex (dexamethasone)
    • 7.4.1. Overview
    • 7.4.2. Clinical Details
  • 7.5. ISTA -Ecabet Sodium
    • 7.5.1. Overview
  • 7.6. Allergan's Androgen Tear
    • 7.6.1. Overview

8. Global Ophthalmology Therapeutics Market - Competitive Landscape

  • 8.1. Allergan, Inc
    • 8.1.1. Business Overview
    • 8.1.2. SWOT
  • 8.2. Merck & Co Inc
    • 8.2.1. Introduction
    • 8.2.2. SWOT
  • 8.3. Novartis AG
    • 8.3.1. Introduction
    • 8.3.2. SWOT
  • 8.4. Pfizer
    • 8.4.1. Business Description
    • 8.4.2. SWOT
  • 8.5. Roche
    • 8.5.1. Introduction
    • 8.5.2. SWOT

9. Global Ophthalmology Therapeutics Market - Strategic Consolidations

  • 9.1. Mergers and Acquisitions
    • 9.1.1. Introduction
    • 9.1.2. Key Mergers and Acquisitions Deals
    • 9.1.3. Segmentation by Geography
    • 9.1.4. Segmentation by Deal Value
  • 9.2. Co-development Deals
    • 9.2.1. Major Co-development Deals
    • 9.2.2. Segmentation by Geography
  • 9.3. Licensing Deals
    • 9.3.1. Major Licensing Deals
    • 9.3.2. Segmentation by Geography
    • 9.3.3. Segmentation by Value

10. Global Ophthalmology Therapeutics Market - Appendix

  • 10.1. Market Definitions
  • 10.2. Abbreviations
  • 10.3. Bibliography
  • 10.4. Research Methodology
    • 10.4.1. Coverage
    • 10.4.2. Secondary Research
    • 10.4.3. Primary Research
  • 10.5. Therapeutic Landscape
    • 10.5.2. Market Size by Geography
  • 10.6. Geographical Landscape
  • 10.7. Pipeline Analysis
  • 10.8. Competitive Landscape
    • 10.8.1. Expert Panel Validation
  • 10.9. Contact Us
  • 10.10. Disclaimer

List of Tables

  • Table 1: Ophthalmology Market, Global, Revenue, ($bn), 2004 - 2011
  • Table 2: Ophthalmology Market, Global, Revenue, ($bn), 2011 - 2018
  • Table 3: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2004 - 2011
  • Table 4: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2011 - 2018
  • Table 5: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004 - 2011
  • Table 6: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2011 - 2018
  • Table 7: Ophthalmology Market, the US, Revenue ($bn), 2004 - 2011
  • Table 8: Ophthalmology Market, the US, Revenue ($bn), 2011 - 2018
  • Table 9: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004 - 2011
  • Table 10: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2011 - 2018
  • Table 11: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004 - 2011
  • Table 12: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2011 - 2018
  • Table 13: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004 - 2011
  • Table 14: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2011 - 2018
  • Table 15: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment, ($), 2004 - 2011
  • Table 16: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011 - 2018
  • Table 17: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004 - 2011
  • Table 18: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011 - 2018
  • Table 19: Ophthalmology Market, Japan, Revenue ($m), 2004 - 2011
  • Table 20: Ophthalmology Market, Japan, Revenue ($m), 2011 - 2018
  • Table 21: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004 - 2011
  • Table 22: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2011 - 2018
  • Table 23: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004 - 2011
  • Table 24: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2011 - 2018
  • Table 25: Ophthalmology Market to 2018, Major Types of Glaucoma
  • Table 26: Ophthalmology Market to 2018, Mechanism of Action of Key Glaucoma Medications
  • Table 27: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004 - 2011
  • Table 28: Ophthalmology Market to 2018, Global, Glaucoma, Revenue Forecast ($bn), 2011 - 2018
  • Table 29: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004 - 2011
  • Table 30: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2011 - 2018
  • Table 31: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004 - 2011
  • Table 32: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2011 - 2018
  • Table 33: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004 - 2011
  • Table 34: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2011 - 2018
  • Table 35: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004 - 2011
  • Table 36: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2011 - 2018
  • Table 37: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004 - 2011
  • Table 38: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2011 - 2018
  • Table 39: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004 - 2011
  • Table 40: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2011 - 2018
  • Table 41: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004 - 2011
  • Table 42: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2011 - 2018
  • Table 43: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004 - 2011
  • Table 44: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2011 - 2018
  • Table 45: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004 - 2011
  • Table 46: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2011 - 2018
  • Table 47: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2004 - 2011
  • Table 48: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2011 - 2018
  • Table 49: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004 - 2011
  • Table 50: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2011 - 2018
  • Table 51: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011 - 2018
  • Table 52: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011 - 2018
  • Table 53: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern (‘000), 2011 - 2018
  • Table 54: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011 - 2018
  • Table 55: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004 - 2011
  • Table 56: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2011 - 2018
  • Table 57: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004 - 2011
  • Table 58: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2011 - 2018
  • Table 59: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004 - 2011
  • Table 60: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2011 - 2018
  • Table 61: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004 - 2011
  • Table 62: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2011 - 2018
  • Table 63: Ophthalmology Market to 2018, PBS Reimbursement List, Australia, 2012
  • Table 64: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009 - 2012
  • Table 65: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009 - 2012
  • Table 66: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009 - 2012
  • Table 67: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009 - 2012
  • Table 68: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009 - 2012

List of Figures

  • Figure 1: Ophthalmology Market to 2018, Global, Revenue, ($bn), 2004 - 2018
  • Figure 2: Ophthalmology Market to 2018, Global, Annual Cost of Treatment, ($), 2004 - 2018
  • Figure 3: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004 - 2018
  • Figure 4: Ophthalmology Market to 2018, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 5: Ophthalmology Market, the US, Revenue ($bn), 2004 - 2018
  • Figure 6: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004 - 2018
  • Figure 7: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 8: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004 - 2018
  • Figure 9: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004 - 2018
  • Figure 10: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 11: Ophthalmology Market, Japan, Revenue ($m), 2004 - 2018
  • Figure 12: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004 - 2018
  • Figure 13: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 14: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004 - 2018
  • Figure 15: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004 - 2018
  • Figure 16: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 17: Ophthalmology Market to 2018, Glaucoma, Treatment Flow Algorithm
  • Figure 18: Ophthalmology Market to 2018, Glaucoma Market, Global, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 19: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004 - 2018
  • Figure 20: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004 - 2018
  • Figure 21: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004 - 2018
  • Figure 22: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 23: Ophthalmology Market to 2018, Allergic Conjunctivitis, Global, Treatment Flow Algorithm
  • Figure 24: Ophthalmology Market to 2018, Branded and Generic Market Share (%), 2011 and 2018
  • Figure 25: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004 - 2018
  • Figure 26: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004 - 2018
  • Figure 27: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004 - 2018
  • Figure 28: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 29: Ophthalmology Market to 2018, Wet Age-Related Macular Degeneration, Global, Treatment Flow Algorithm
  • Figure 30: Ophthalmology Market to 2018, Wet-Age Related Macular Degeneration, Global, Branded and Generic Market Share (%), 2011 - 2018
  • Figure 31: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004 - 2018
  • Figure 32: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011 - 2018
  • Figure 33: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011 - 2018
  • Figure 34: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern (‘000), 2004 - 2018
  • Figure 35: Ophthalmology Market to 2018, Diabetic Macular Edema, Global, Treatment Flow Algorithm
  • Figure 36: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011 - 2018
  • Figure 37: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004 - 2018
  • Figure 38: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004 - 2018
  • Figure 39: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004 - 2018
  • Figure 40: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Treatment Flow Algorithm, 2011
  • Figure 41: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Branded and Generic Market Share (%), 2011 - 2018
  • Figure 42: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004 - 2018
  • Figure 43: Ophthalmology Market to 2018, Allergan, SWOT, 2012
  • Figure 44: Ophthalmology Market to 2018, Merck Co & Inc, SWOT, 2012
  • Figure 45: Ophthalmology Market to 2018, Novartis AG, SWOT, 2012
  • Figure 46: Ophthalmology Market to 2018, Pfizer, SWOT, 2012
  • Figure 47: Ophthalmology Market to 2018, Roche, SWOT, 2012
  • Figure 48: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009 - 2012
  • Figure 49: Ophthalmology Market to 2018, Global, Segmentation of Deals by Value (%),2009 - 2012
  • Figure 50: Ophthalmology Market to 2018 Global, Number of Deals by Geography (%),2009 - 2012
  • Figure 51: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009 - 2012
  • Figure 52: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value (%), 2009 - 2012
  • Figure 53: GBI Research Market Forecasting Model
Back to Top